Abbott acquires leading colorectal cancer early screening company Exact Sciences for $2.1 billion.

Abbott and Exact Sciences announced on November 20 that they have reached a final agreement for Abbott to acquire the leading colorectal cancer screening company, Exact Sciences. Under the terms of the agreement, Exact Sciences shareholders will receive a purchase price of $105 per share of common stock, with a total equity value of approximately $21 billion.